Exelixis, Inc. (NASDAQ:EXEL)
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
stockgame101
(88.42)
Submitted: 12/5/2007 4:10:36 AM :
Start Price:
$8.33
EXEL Score:
-38.21
This is a long shot - deep pipeline is the ONLY reason I am making this speculative call. Hoping law of statistics kick in and make this a winner... Even one blockbuster drug can mean huge margin growth from here. Am currently down 18% of this actual stock position - so have a safety buffer here to recommend in CAPS :-)
Recs
foolsfool11
(95.27)
Submitted: 12/2/2007 12:17:05 AM :
Start Price:
$8.74
EXEL Score:
-40.65
Good prod pipeline, pharma cred, budding biotech... trading close to 20% below 200-day moving average presents good buying opportunity (if you can stomach high price volatility)
Recs
StevenSSK11
(82.17)
Submitted: 11/19/2007 5:56:52 PM :
Start Price:
$8.65
EXEL Score:
-42.80
Ripe pipeline and beaten down price. Here they come!
Recs
Smittyc5
(< 20)
Submitted: 11/16/2007 1:16:06 PM :
Start Price:
$8.70
EXEL Score:
-42.05
slight set back but RB core pick - I believe
Recs
devilfish88
(90.01)
Submitted: 11/15/2007 12:44:45 AM :
Start Price:
$9.10
EXEL Score:
-43.77
Great management, top of the line drug research (currently 14 drug pipeline), and partnerships with big pharm (ex: GSK). Likely long term winner that looks extremely attractive at these levels.
Recs
pokergod
(24.02)
Submitted: 11/13/2007 2:30:12 PM :
Start Price:
$8.97
EXEL Score:
-42.95
Great entry point, under nine bucks.
Recs
Charleroi
(< 20)
Submitted: 11/9/2007 10:28:53 PM :
Start Price:
$9.02
EXEL Score:
-44.20
Great pipeline! Should pay off sometime.
Recs
spincus614
(< 20)
Submitted: 11/6/2007 3:18:29 PM :
Start Price:
$9.46
EXEL Score:
-42.65
A deep, promising pipeline. Market WAY over-reacted to 3Q report. I don't think it is unusual for a drug company at this stage of development to have a quarter like Exelixis did. Time to load up on this one on this short-term weakness in the price. Should outperform once Glaxo picks up its first partner drug. This stock should ultimately be a multi-bagger, especially if one buys in at today's bargain price!
Recs
rmcbirney
(99.26)
Submitted: 10/25/2007 1:42:13 PM :
Start Price:
$10.91
EXEL Score:
-49.69
cancer shancer
Recs
mike282
(45.76)
Submitted: 10/25/2007 9:56:01 AM :
Start Price:
$11.24
EXEL Score:
-50.55
Got deep drug pipeline, and i have real money riding with this RB pick! Just 1 to 2 drugs approval that's all it takes!
Recs
cristofero
(< 20)
Submitted: 10/23/2007 8:35:52 PM :
Start Price:
$11.31
EXEL Score:
-50.77
Just going along with RB (I want a rating, and a cap).
Recs
halogen25
(88.78)
Submitted: 10/10/2007 2:18:01 AM :
Start Price:
$11.46
EXEL Score:
-48.47
Lots in the pipeline, with several partners. Looks promising.
Recs
clayton16
(64.17)
Submitted: 10/6/2007 7:41:57 PM :
Start Price:
$11.10
EXEL Score:
-47.54
Stole it from Motley fool Rule Breakers. Nice Chart
Recs
Recs
tycoon999
(< 20)
Submitted: 9/21/2007 12:35:22 AM :
Start Price:
$11.19
EXEL Score:
+49.43
This is a pathetic biopharm company. All pipeline products are of early stage, with no specific timeline of commercialization. Milestone payments are not BIG, and royalties will not kick in until years after, plus the uncertainty.
This company needs to suck up new $ every 6 to 9 months. Executives are paid fat, and options and stuff. And it is absolutely NO good for investors.
Recs
Curleyjack
(< 20)
Submitted: 8/30/2007 6:34:52 PM :
Start Price:
$11.13
EXEL Score:
-52.76
Many prospects on track.
Recs
Bramps
(< 20)
Submitted: 8/30/2007 10:32:41 AM :
Start Price:
$11.14
EXEL Score:
-53.72
The performance of the R & D techs has been outstanding. Given that they do not have any products in market, the sheer numbers and seeming quality of the products make it a very good bet that one will emerge. I reference the quality only by the interest shown by other large caps in the industry. I feel it shows a lack of development on their part and further excites this pick. Amen!!
Recs
hpstocks50
(< 20)
Submitted: 8/29/2007 7:42:41 PM :
Start Price:
$11.03
EXEL Score:
-53.81
I think GSK will take XL880. This nearest term (which his still 2.5 to 3 years away from market, the premise it gets approved) MET inhibitor has broad application in several tumor types. Also, don't forget that FDA LOVES oral antineoplastic approaches, in terms of lower admin. costs.
Recs
bradaronson
(21.52)
Submitted: 8/29/2007 12:07:39 PM :
Start Price:
$10.98
EXEL Score:
-53.84
May take 2 years, may take 5 years. This stock will grow big, but you can't time it. Just buy now and wait thru the volitility. Buy more if it drops to 10.5.
Recs
mwd03
(86.20)
Submitted: 8/22/2007 4:51:33 PM :
Start Price:
$11.00
EXEL Score:
-52.47
Strong looking stock for the long-term investor. A number of drug treatments in the pipeline. Big companies have shown interest in partnering up. Only need a small percentage of their treatments to be approved. They have some promising drugs in various stages of testing.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 181 - 200 of 392 : « Previous 5 6 7 8 9 10 11 12 13 14 Next »